Navigation Links
Halo Therapeutics Reports Favorable Independent Review of Lead Drug Candidate HT-100
Date:3/20/2012

NEWTON, Mass., March 20, 2012 /PRNewswire/ -- Halo Therapeutics, LLC, a clinical-stage biopharmaceutical company developing novel therapeutics for rare fibrotic diseases, announced today that the TREAT-NMD Advisory Committee on Therapeutics (TACT) has reviewed HT-100, Halo's drug candidate for Duchenne muscular dystrophy (DMD), and believes the compound has potential based on the proposed mechanism. TREAT-NMD is a global network dedicated to expediting the delivery of promising new therapies to patients with neuromuscular disease. TACT provides independent, objective guidance on the therapeutic potential of drug candidates (novel or repurposed), which are submitted for review on a voluntary basis. In its review of HT-100, TACT found the drug candidate to be "ready for the clinic."

"TACT offers the opportunity for objective review of potential new therapies to help industry, researchers and patient advocacy groups. The review provides multi-disciplinary advice on the development of the potential therapies in the context of a realistic development pathway," said Volker Straub of TREAT-NMD. "TACT evaluated the proposal from Halo Therapeutics and felt it was well prepared, and that the compound has potential based on the proposed mechanism. Overall the plan to progress to a clinical trial is realistic."

DMD is a progressive and fatal neuromuscular disorder that afflicts approximately 1 in 3,500 boys worldwide.  HT-100, Halo's proprietary formulation of halofuginone, is an orally available small molecule drug candidate intended to reduce fibrosis and promote healthy muscle fiber regeneration. HT-100 works by inhibiting the pathological fibrotic process in muscle and directly stimulating healthy muscle fiber regeneration. The U.S. Food and Drug Administration recently granted orphan drug designation to HT-100. The company will begin a phase 2 study in the second half of 2012.

"We submitted HT-100 for a TACT review knowing that informed, objective feedback on our pre-clinical data and development plans would be invaluable to our efforts," said Marc Blaustein, CEO of Halo Therapeutics. "We believe their recommendations for HT-100's advancement will hasten our progress toward delivering a safe and effective new therapy for DMD patients and their families."

A brief summary of TACT's review of HT-100 can be found at http://www.treat-nmd.eu/resources/tact/reviews/past/halofuginone-ht-100/.

About Duchenne Muscular Dystrophy
Duchenne muscular dystrophy is caused by a mutation in the dystrophin gene, resulting in progressive muscle weakness. The disease manifests itself first in weakened skeletal muscles and eventually results in cardiac and pulmonary impairment. Corticosteroids are the current standard of care treatment for DMD.  While this treatment delays disease progression by several years, their prolonged use is typically associated with side effects and the treatment does not alter the ultimate outcome of the disease. Young men with Duchenne typically live into their twenties or early thirties.

About TREAT-NMD
TREAT-NMD is a neuromuscular network that has developed the infrastructure to ensure that promising therapies reach patients as quickly as possible. TREAT-NMD was funded as a network of excellence by the EU with the FP6 programme (contract number: 036825) from January 2007 – December 2011.  Since its launch the network's focus has been on the development of tools that industry, clinicians and scientists need in order to bring novel therapeutic approaches through preclinical development and into the clinic, and on establishing best-practice clinical care for neuromuscular patients worldwide.

About Halo Therapeutics
Based in Newton, Mass., Halo Therapeutics, LLC, is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for rare fibrotic diseases like Duchenne muscular dystrophy. Founded through a collaboration between patient advocacy organizations and industry veterans, the company is partnering with the clinical community and patients to transform therapeutic options and, by extension, lives. For more information, please visit www.halotherapeutics.com.Media Contacts  Name:

Marc B. BlausteinCompany:

Halo Therapeutics, LLCPhone Number:

617.431.7250Email address:

mblaustein@halotherapeutics.com  


'/>"/>
SOURCE Halo Therapeutics, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Echo Therapeutics, Inc. Announces 2011 Financial Results
2. Stemline Therapeutics Appoints Kevin Buchi, Former CEO of Cephalon, to Its Board of Directors
3. Nile Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting
4. Prime Therapeutics Announces CareCentered Contract™ with EMD Serono, Inc. for MS Drug Rebif®
5. ADHD Therapeutics Reviewed by NeuroPerspective
6. Cell Therapeutics, Inc. (CTI) Reports Fourth Quarter and Year-End Financial Results and Milestones
7. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End 2011 Financial Results on March 7
8. Particle Sciences Acquires Exclusive License to Lyotropic Therapeutics Drug Delivery Technology
9. Nektar Therapeutics Reports Fourth Quarter and Year-End 2011 Financial Results
10. Nektar Therapeutics Announces Agreement to Sell CIMZIA® and MIRCERA® Royalties to Royalty Pharma for $124 Million
11. Halozyme Therapeutics to Present at the CITI 2012 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... India , January 12, 2017 ... titled, "IVD Quality Control Products Market by Product Type, by ... Opportunity Analysis and Industry Forecast, 2014 - 2022" The global ... in 2015, and is expected to reach $1,052 million by ... The quality controls products segment dominated the market with fourth-fifths ...
(Date:1/12/2017)... LONDON , Jan. 12, 2017 ... health benefits when consumed, which facilitate digestion, gastrointestinal ... There have been 500 million probiotics ... can realize 15% in some European countries. The ... in the developed countries. In developed countries, ...
(Date:1/12/2017)... , Jan. 12, 2017 "Global ... report analyzes ongoing clinical and non-clinical trends in ... are 3 lung cancer vaccines commercially available in ... trial of 30 lung cancer vaccines in clinical ... parameters associated with the development of the lung ...
Breaking Medicine Technology:
(Date:1/13/2017)... ... 2017 , ... People who have sensitive teeth are about as common as ... teeth. Sadly, most dental hygiene products in the market contain chemical ingredients that only ... continuing their daily oral care routine to keep their teeth white and healthy is ...
(Date:1/13/2017)... , ... January 13, 2017 , ... Friday, January 13 ... of the game room, increasing the size of the location to 90,000 square feet. ... 8-hole mini golf course that takes customers on an educational tour of the historic ...
(Date:1/13/2017)... ... ... MyGenetx, a molecular laboratory headquartered in middle Tennessee is proud to announce ... LD, will serve on the 2017 TBCC Board. , Kris Wiese was ... year as Vice President. She will oversee the newly elected board of 17. Mary ...
(Date:1/13/2017)... CO (PRWEB) , ... January 13, 2017 , ... As ... a growing alliance of deans of colleges and schools of education across the country ... schools. , In a Declaration of Principles released today, 175 deans sounded the alarm: ...
(Date:1/13/2017)... ... ... Overseer at The House of Yahweh, has published a new article that refutes false accusations ... eternal joy. Yisrayl says he has been accused of being the “prophet of doom,” when ... are nothing new in his world and says it has always been that way for ...
Breaking Medicine News(10 mins):